연구업적

연구

연구
연구업적

최근 5년 연구업적 현황

연도		2023년	2022년	2021년	2020년	2019년
SCI 논문 발표편수	책임	173편	163편	184편	135편	144편
SCI 논문 발표편수	공동	120편	115편	136편	168편	167편
합계		293편	278편	320편	303편	311편

2881. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis

Ryan Shea Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee , Abner Herbert Lim , Seri Park5, Yeon Hee Park , Ching-Hung Lin , Yen-Shen Lu , Makiko Ono , Takayuki Ueno, Yoichi Naito , Tatsuya Onishi, Geok-Hoon Lim , Su-Ming Tan , Han-Byoel Lee , Han Suk Ryu , Wonshik Han , Veronique Kiak Mien Tan , Fuh-Yong Wong , Seock-Ah Im, Puay Hoon Tan , Jason Yongsheng Chan, Yoon-Sim Yap

BMC medicine 2022. 20(1):105 Link

2880. The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology

Kelly A Hirko, Gabrielle Rocque, Erica Reasor, Ammanuel Taye, Alex Daly, Ramsey I Cutress, Ellen R Copson, Dae-Won Lee, Kyung-Hun Lee, Seock-Ah Im, Yeon Hee Park

BMC medicine 2022. 20(1):72. Link

2879. Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roché HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA.

Clin Cancer Res. 2022 Apr 1;28(7):1383-1390. Link

2878. Increased Apoptotic Activity in Low-Risk Myelodysplastic Syndrome

Park S, Shin DY, Park JS, Park HS, Moon SY, Yoon SS, Lee DS

J Clin Med. 2022 Aug 7;11(15):4604 Link

2877. Double-stranded RNA induction asa potential dynamic biomarkerfor DNA-demethylating agents

Kang M, Kharbash R, Byun JM, Jeon J, Ali AA, Ku D, Yoon J, Ku Y, Sohn J, Lee SV, Shin DY, Koh Y, Yoon SS, Hong J, Kim Y

Mol Ther Nucleic Acids. 2022 Jul 21;29:370-383 Link

2876. Evaluation of Optimal Assessment Schedules for Surveillance After Definitive Locoregional Treatment of Locally Advanced Head and Neck Cancer: A Retrospective Cohort Study With Parametric Modeling of Event-Free Survival

Lee HI, Lee J, Lee JH, Wu HG, Kim JH, Kim Y, Eom KY

JAMA Otolaryngol Head Neck Surg . 2022 Sep 29;e222561. doi: 10.1001/jamaoto.2022.2561. Online ahead of print Link

2875. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

Funda Meric-Bernstam 1, Muralidhar Beeram 2, Erika Hamilton 3, Do-Youn Oh 4, Diana L Hanna 5, Yoon-Koo Kang 6, Elena Elimova 7, Jorge Chaves 8, Rachel Goodwin 9, Jeeyun Lee 10, Lisle Nabell 11, Sun Young Rha 12, Jose Mayordomo 13, Anthony El-Khoueiry 14, Shubham Pant 15, Kanwal Raghav 15, Jin Won Kim 16, Amita Patnaik 2, Todd Gray 17, Rupert Davies 17, Mark A Ozog 17, Joseph Woolery 17, Keun-Wook Lee 16

Lancet Oncol. 2022 Dec;23(12):1558-1570 Link

2874. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Hedy L Kindler 1, Pascal Hammel 2, Michele Reni 3, Eric Van Cutsem 4, Teresa Macarulla 5, Michael J Hall 6, Joon Oh Park 7, Daniel Hochhauser 8, Dirk Arnold 9, Do-Youn Oh 10, Anke Reinacher-Schick 11, Giampaolo Tortora 12, Hana Algül 13, Eileen M O'Reilly 14, Sonal Bordia 15, David McGuinness 16, Karen Cui 17, Gershon Y Locker 17, Talia Golan 18

J Clin Oncol. 2022 Dec 1;40(34):3929-3939. Link

2873. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A

D V T Catenacci 1, Y-K Kang 2, H H Yoon 3, B Y Shim 4, S T Kim 5, D-Y Oh 6, A I Spira 7, S V Ulahannan 8, E J Avery 9, P M Boland 10, J Chao 11, H C Chung 12, F Gardner 13, S J Klempner 14, K-W Lee 15, S C Oh 16, J Peguero 17, M B Sonbol 18, L Shen 19, M Moehler 20, J Sun 21, D Li 21, M K Rosales 21, H Park 22

ESMO Open. 2022 Oct;7(5):100563 Link

2872. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

M Maio 1, P A Ascierto 2, L Manzyuk 3, D Motola-Kuba 4, N Penel 5, P A Cassier 6, G M Bariani 7, A De Jesus Acosta 8, T Doi 9, F Longo 10, W H Miller 11, D-Y Oh 12, M Gottfried 13, L Xu 14, F Jin 14, K Norwood 14, A Marabelle 15

Ann Oncol. 2022 Sep;33(9):929-938. Link